Methanol poisoning as a new world challenge: A review.

Ann Med Surg (Lond)

Toxoplasmosis Research Center, Communicable Diseases Institute, Iranian National Registry Center for Lophomoniasis and Toxoplasmosis, Mazandaran University of Medical Sciences, Sari, Iran.

Published: June 2021

Background: Methanol poisoning (MP) occurs often via ingestion, inhalation, or dermal exposure to formulations containing methanol in base. Clinical manifestations of MP include gastrointestinal symptoms, central nervous system (CNS) suppression, and decompensated metabolic acidosis occurred with blurred vision and early or late blindness.

Objective: This study reviewed the clinical manifestations, laboratory and radiology findings, and treatment approaches in MP.

Discussion: Methanol is usually rapidly absorbed after ingestion and metabolized by alcohol dehydrogenase (ADH), then distributed to the body water to reach a volume distribution approximately equal to 0.77 L/kg. It is also eliminated from the body as unchanged parent compounds. Clinical manifestations of MP alone initiate within 0.5-4 h after ingestion and include gastrointestinal symptoms and CNS suppression. After a latent period of 6-24 h, depending on the absorbed dose, decompensated metabolic acidosis occurs with blurred vision and early or late blindness. Blurred vision with normal consciousness is a strong suspicious sign of an MP. The mortality and severity of intoxication are well associated with the severity of CNS depression, hyperglycemia, and metabolic acidosis, but not with serum methanol concentration. After initial resuscitation, the most important therapeutic action for patients with known or suspected MP is correction of acidosis, inhibition of ADH, and hemodialysis.

Conclusion: Since MP is associated with high morbidity and mortality, it should be considered seriously and instantly managed. Delay in treatment may cause complications, permanent damage, and even death.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187162PMC
http://dx.doi.org/10.1016/j.amsu.2021.102445DOI Listing

Publication Analysis

Top Keywords

clinical manifestations
12
metabolic acidosis
12
blurred vision
12
methanol poisoning
8
include gastrointestinal
8
gastrointestinal symptoms
8
cns suppression
8
decompensated metabolic
8
vision early
8
early late
8

Similar Publications

Lupus disease activity state and Foxp3 gene polymorphism.

Egypt J Immunol

January 2025

Department of Medical Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.

The autoimmune disease systemic lupus erythematosus (SLE) is presented with many clinical symptoms. The transcription factor fork head box protein 3 (Foxp3) is expressed on regulatory T (T-reg) cells and essential for its development and function. Functional single-nucleotide polymorphisms (SNPs) in the Foxp3-3279 (rs3761548 C/A) gene influence SLE pathogenesis.

View Article and Find Full Text PDF

A neurocomputational account of multi-line electronic gambling machines.

Trends Cogn Sci

January 2025

Department of Psychology, Biological Psychology, University of Cologne, Cologne, Germany. Electronic address:

Multi-line electronic gambling machines (EGMs) are strongly associated with problem gambling. Dopamine (DA) plays a central role in substance-use disorders, which share clinical and behavioral features with disordered gambling. The structural design features of multi-line EGMs likely lead to the elicitation of various dopaminergic effects within their nested anticipation-outcome structure.

View Article and Find Full Text PDF

Lupus nephritis: Biomarkers.

Adv Clin Chem

January 2025

University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, ON, Canada. Electronic address:

Lupus nephritis (LN) or renal involvement of systemic lupus erythematosus (SLE), is a common manifestation occurring in at least 50 % of SLE patients. LN remains a significant source of morbidity, often leading to progressive renal dysfunction and is a major cause of death in SLE. Despite these challenges, advances in the understanding of the pathogenesis and genetic underpinnings of LN have led to a commendable expansion in available treatments over the past decade.

View Article and Find Full Text PDF

Emerging biomarkers in Gaucher disease.

Adv Clin Chem

January 2025

Center for Orphan Drug Research, Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, United States. Electronic address:

Gaucher disease (GD) is a rare lysosomal disorder characterized by the accumulation of glycosphingolipids in macrophages resulting from glucocerebrosidase (GCase) deficiency. The accumulation of toxic substrates, which causes the hallmark symptoms of GD, is dependent on the extent of enzyme dysfunction. Accordingly, three distinct subtypes have been recognized, with type 1 GD (GD1) as the common and milder form, while types 2 (GD2) and 3 (GD3) are categorized as neuronopathic and severe.

View Article and Find Full Text PDF

Thyroid hormones in systemic lupus erythematosus: the catalyst for disease progression?

Am J Med Sci

January 2025

Henan Provincial People's Hospital, Henan Provincial Clinical Research Center for Kidney Disease, Henan Key Laboratory of Nephrology and Immunology, Zhengzhou 450003, Henan, China. Electronic address:

Objective: The study aimed to investigate the impact of varying thyroid function statuses on clinical and laboratory indicators in patients with systemic lupus erythematosus (SLE).

Methods: A retrospective analysis was conducted on 258 patients with SLE, who were stratified according to thyroid function, renal involvement, and disease activity. The predictive value of thyroid hormones was evaluated using a receiver operating characteristic (ROC) curve.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!